Teneo excimer laser platform approved for LASIK correction of myopia, myopic astigmatism
Click Here to Manage Email Alerts
Key takeaways:
- The Teneo excimer laser platform is indicated for the correction of myopia and myopic astigmatism.
- The platform offers advances in accuracy, efficiency and usability.
The FDA approved the Teneo excimer laser platform for LASIK vision correction surgery for myopia and myopic astigmatism, according to a press release from Bausch + Lomb.
The platform includes a high-speed laser that operates at 500 Hz and an advanced eye tracker that operates at 1,740 Hz.
Teneo is the smallest excimer laser unit available in the U.S. and is designed to streamline the surgical process with a customizable graphical user interface touchscreen. The software treats the manifest refraction and eliminates the need for a nomogram, and the platform has a 360° swiveling microscope that adapts to surgeon height and posture.
It is indicated for LASIK to reduce or eliminate myopic astigmatism up to –10 D manifest refraction spherical equivalent, with sphere between –1 D and cylinder between 0 D and –3 D, in patients who are 22 years of age or older with a stable refraction for 12 months.
The approval is the first in nearly 2 decades for an excimer platform, according to the release.
“FDA approval of Teneo represents a major milestone for the advancement of laser vision correction technology in the United States,” George O. Waring IV, MD, FACS, founder and medical director of Waring Vision Institute, Mt. Pleasant, South Carolina, said in the release. “In addition to the technological advantages Teneo offers, the open air feeling around the laser and quiet performance contribute to a comfortable experience for the patient.”
Perspective
Back to Top
When we see all the improvements in cataract surgery and refractive surgery, two of the most successful surgeries in all of medicine, I'm proud to be an ophthalmologist. This is true of the newly approved Teneo excimer laser by Bausch + Lomb.
As we know, laser vision correction is one of the most precise and patient satisfying surgeries in existence, and the new approval of the Bausch + Lomb laser continues to advance refractive surgery.
There are a couple of ways to innovate with technology today. One is through safety and outcomes, and the other is through patient and surgeon experience. The Teneo does both. The advanced eye tracking at 1,740 Hz and the 500 Hz ablation time leads to quick and safe surgery, with less time for the corneal bed to dry. The laser also has an intuitive user interface and a more open experience for the patient who's under the laser.
Our center was in the Teneo FDA monitored clinical trials and we had a great experience in the trial. Lastly, space constraints can be a problem for many practices, and the small footprint of this laser makes it easier to replace prior lasers or add a laser for the first time in a practice that doesn't have much available space.
Read more about
Click Here to Manage Email Alerts